Musical company

LUCID Partners with Japanese Pharmaceutical Company to Develop Personalized Music Treatment for Alzheimer’s Disease

TORONTO–(BUSINESS WIRE).

Alzheimer’s disease is more than just memory loss – neuropsychiatric symptoms can include anxiety, aggression and personality changes. These symptoms are not only heartbreaking, they promote caregiver burnout. Treatment is needed more than ever.

“People living with Alzheimer’s disease deserve dignity at this point in their lives,” said Zach McMahon, CEO and co-founder of LUCID. “They deserve treatment that is both effective and likely to improve their quality of life and that of their caregivers.”

Earlier this year, the first randomized controlled clinical trial of LUCID demonstrated clinical evidence for the reduction of acute anxiety in adults with moderate anxiety. With JT’s support, LUCID will translate its data-driven clinical knowledge into the development of a digital therapy to reduce agitation and anxiety in dementia care, initially with Alzheimer’s disease.

“Musical interventions can alleviate these psychiatric symptoms and induce joy,” McMahon said. “We are committed to providing new paradigms of evidence-based care. »

Now, with funding from JT, LUCID will conduct research and development of the digital therapy that will be known as LUC-101. Sheridan College Seniors Research Center is also involved in the development of LUC-101 through a Natural Sciences and Engineering Research Council of Canada (NSERC) initiative to support research and design in gerontology.

LUCID will take a leadership position in bringing the power of music as medicine to patients and caregivers around the world. With LUC-101, LUCID strives to deliver the benefits of personalized music therapy for Alzheimer’s disease while lowering the overall cost and barrier to entry through AI technology and apps compatible with the cloud.

About LUCID

LUCID develops therapeutic musical experiences for mental health. By unleashing the power of neuroscience and machine learning, LUCID’s AI curates musical experiences optimized for specific emotional outcomes. They aim to provide personalized, evidence-based and accessible mental health care solutions. LUCID is working towards the clinical validation of music as medicine.

LUCID’s latest clinical trial is The effect of music and auditory beat stimulation on anxiety. For more information, please visit www.thelucidproject.ca.

About J.T.

JT, Japan Tobacco Inc., owns a pharmaceutical company that focuses on the research and development, manufacture and sale of prescription drugs. For more information, please visit https://www.jt.com/about/division/pharma/index.html.